What it is
Voclosporin is a ring of eleven amino acids — a cyclic peptide — and a close chemical relative of cyclosporine. It is sold in the United States as Lupkynis, approved on 22 January 2021 for adults with active lupus nephritis, the kidney inflammation that affects many people with systemic lupus (Drugs@FDA, NDA 213716, sponsor Aurinia).
The label's chemical name lists the eleven residues of the ring: one unusual amino acid with a long side chain, then α-aminobutyric acid, N-methylglycine, N-methylleucine, valine, N-methylleucine, alanine, D-alanine and three more N-methylated residues. That is the cyclosporine ring. The difference sits in the first residue, whose side chain is written on the label as a (6E)-nonadienoyl group (Lupkynis label, section 11, revision dated 2026-08-25). The label also notes that the drug substance is 90–95% the trans form of that side chain.
| Property | Value | Source |
|---|---|---|
| Length | 11 amino acids, cyclic | Lupkynis label, section 11 |
| Formula | C63H111N11O12 | Lupkynis label |
| Molecular weight | 1,214.6 g/mol | Lupkynis label |
| Solubility | Practically insoluble in water (under 0.1 g/L at 20 °C) | Lupkynis label |
| Form sold | Soft gelatin capsule, 7.9 mg | Lupkynis label, section 3 |
The site's cyclosporine entry covers the parent molecule.
How it works
Voclosporin is a calcineurin inhibitor. Calcineurin is an enzyme inside T cells, a type of white blood cell; when it is switched on, the cell produces signals that drive inflammation. Blocking it damps that response. The label places voclosporin in the same drug class as cyclosporine and tacrolimus. In lupus nephritis the immune system attacks the kidney's filters, so suppressing it aims to stop the damage and reduce the protein leaking into the urine.
What the trials showed
The approval rests on AURORA 1, a 52-week, randomised, double-blind trial at 142 sites in 27 countries, published in the Lancet in 2021 (PMID 33971155). It enrolled 357 adults with biopsy-proven lupus nephritis. Every patient received mycophenolate mofetil and a tapering course of low-dose steroids; half also received voclosporin, half placebo.
| Outcome at week 52 | Voclosporin | Placebo | Source |
|---|---|---|---|
| Complete renal response | 73 of 179 (41%) | 40 of 178 (23%) | AURORA 1 abstract |
| Odds ratio | 2.65 (95% CI 1.64–4.27) | — | AURORA 1 abstract |
| Serious adverse events | 37 of 178 (21%) | 38 of 178 (21%) | AURORA 1 abstract |
| Pneumonia (serious) | 7 (4%) | 8 (4%) | AURORA 1 abstract |
| Deaths | 1 | 5 | AURORA 1 abstract |
"Complete renal response" had a strict definition on the label: urine protein-to-creatinine ratio of 0.5 mg/mg or less, kidney function held, and no more than a low steroid dose late in the year. A patient who needed rescue medication counted as a non-responder.
The earlier AURA-LV trial (Kidney International 2019, PMID 30420324) compared two voclosporin doses with placebo on the same background treatment; it is the dose-ranging study AURORA 1 followed.
What the record does not establish: AURORA 1 measured one year. Whether the higher response rate prevents kidney failure over a decade is not shown by these trials, and the label states that safety and efficacy have not been established with cyclophosphamide, another common lupus nephritis drug.
Safety on the label
The Lupkynis label carries a boxed warning: an increased risk of malignancies and serious infections, with voclosporin as with other immunosuppressants, that may lead to hospitalisation or death.
The label describes a studied regimen of 23.7 mg twice daily, three of the 7.9 mg capsules per dose. That figure is reported here because it is on the label; dosing is decided by the prescriber.
Where it stands
Voclosporin is a prescription drug with one US indication. It is not a supplement, a research peptide or a wellness product, and nothing on the record supports using it outside lupus nephritis. Decisions about it belong to the nephrologist or rheumatologist treating the kidney disease.
Sources opened 2026-11-16: Lupkynis prescribing information (openFDA, revision 2026-08-25); Drugs@FDA NDA 213716; Rovin et al., Lancet 2021 (PMID 33971155); Rovin et al., Kidney International 2019 (PMID 30420324); PubMed and ClinicalTrials.gov API v2 counts.
